COVID-19 vaccine stocks have been some of the most explosive.
Just over the last few weeks:
· Moderna (MRNA) ran from $60 to $83.56
· BioNTech (BNTX) from $62 to $77.05
· Pfizer (PFE) ran from $33 to $36.13
· Inovio Phamaceuticals (INO) ran from $20 to $25.64
· Vaxart Inc. (VXRT) ran from $8 to $16
While each of those could easily run higher on vaccine progress, another one to keep an eye on is AstraZeneca (AZN).
Reportedly, by July 20, a medical journal is expected to release positive news on the coronavirus vaccine the company is developing with University of Oxford researchers, according to Bloomberg. “Results from early tests of the vaccine in people will be published by The Lancet.”
Anticipation of good, solid news has already sent the AZN stock from $53.73 to $57.44. But it could move higher on a positive report.
Better, according to FX Empire:
“Earlier this month, the British-Swedish multinational pharmaceutical and biopharmaceutical company, said that they were satisfied by the immune response they witnessed during the trials and were anticipating to officially publish the outcome by the end of the month. Also, the WHO’s chief scientist said last month that AstraZeneca’s COVID-19 vaccine, known as AZD1222, was the most advanced in terms of development.”